SavedAdd your journal

Journals / Bozok Tıp Dergisi / 2013 / Cilt: 3 Sayı: 3

Clinical Outcomes of Radioactive Iodine Therapy in a Patient with Myasthenia Gravis and Hyperthyroidism

MYASTHENİA GRAVİSLİ HİPERTİROİDİ HASTASINDA RADYOAKTİF İYOT TEDAVİSİNİN KLİNİK SONUÇLARI

Füsun Aydoğan
Akın Aydoğan
Seçkin Akküçük
İhsan Üstün
Cumali Gökçe
Mustafa Uğur
Pages
69–71
Publication Date
2013-09-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Radioactive iodine therapy was applied to the patient and after 3 months of medication the patient become euthyroid and clinical findings of myasthenia were regressed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Myasthenia Gravis is an autoimmune disease characterized with muscle weakness and fatigue.
📊
Key Findings & Data:Hyperthyroidism can be present with Myasthenia Gravis with a rate of 2-17.5 %.
💡
Conclusion & Impact:Radioactive iodine therapy was applied to the patient and after 3 months of medication the patient become euthyroid and clinical findings of myasthenia were regressed.
🔬Design:Makale
📍Scope:Comprehensive Sample
⚙️Variables:Myasthenia gravis · Hipertiroidi · Radyoaktif iyot tedavisi

Abstract

Myasthenia Gravis is an autoimmune disease characterized with muscle weakness and fatigue. Hyperthyroidism can be present with Myasthenia Gravis with a rate of 2-17.5 %. It is known that hyperthyroidism affects the clinical course of myasthenia gravis. A 27 years old woman with myasthenia gravis and recently occurred hyperthyroidism is presented in this study. Radioactive iodine therapy was applied to the patient and after 3 months of medication the patient become euthyroid and clinical findings of myasthenia were regressed.

Özet

Miyastenia gravis kas güçsüzlüğü ve yorgunlukla karakterize otoimmün bir hastalıktır. Myastenia gravis diğer otoimmun hastalıklar ile birlikte görülebilir. Miyastenia gravis hastalarında % 2-17.5 hipertiroidizm görülür. Hipertiroidizmin myastenia gravis klinik seyrini etkilediği bildirilmektedir. Bu vaka takdiminde miyastenia gravisi bulunan ve 3 ay önce hipertiroidi teşhisi konulan 27 yaşında bir bayan hasta sunulmuştur. Olguya, rad- yoaktif iyot tedavisi uygulanmış ve 3 ay sonra ötiroid olduğu ve miyestania şikâyetlerinin tedaviye daha iyi yanıt verdiği izlenmiştir.

🔖

Cite This Article

Aydoğan, F., Aydoğan, A., Akküçük, S., Üstün, İ., Gökçe, C., Uğur, M. (2013). Clinical Outcomes of Radioactive Iodine Therapy in a Patient with Myasthenia Gravis and Hyperthyroidism. Bozok Tıp Dergisi, Cilt: 3 Sayı: 3, 69–71. https://ajindex.com/articles/1378051

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Drachman DB. Myasthenia gravis. N Engl J Med 1994;330:1797-810.
  2. Ratanakorn D, Vejjajiva A. Long-term follow-up of myasthenia gravis patients with hyperthyroidism. Acta Neurol Scand 2002;106(2):93-8.
  3. Marinó M, Ricciardi R, Pinchera A, Barbesino G, Manetti L, Chiovato L, Braverman LE, Rossi B, Muratorio A, Mariotti S.Mild clinical expression of myasthenia gravis associated with autoimmune thyroid diseases. J Clin Endocrinol Metab 1997; 82(2):438-43.
  4. Datt V, Tempe DK, Singh B, Tomar AS, Banerjee A, Dutta D, Bhandari H.Anesthetic management of patient with myasthenia gravis and uncontrolled hyperthyroidism for thymectomy. Ann Card Anaesth 2010;13(1):49-52.
  5. Trabelsi L, Charfi N, Triki Ch, Mnif M, Rekik N, Mhiri Ch, Abid M. Myasthenia gravis and hyperthyroidism: two cases. Ann Endocrinol (Paris) 2006;67(3):265-9.
  6. Moura-Neto A, Mosci C, Santos AO, Amorim BJ, de Lima MC, Etchebehere EC, Tambascia MA, Ramos CD, Zantut-Wittmann DE. Predictive factors of failure in a fixed 15 mCi 131I-iodide therapy for Graves’ disease. Clin Nucl Med 2012;37(6):550-4.
  7. Freedman S.Antisemitism and the history of myasthenia gravis. Isr Med Assoc J 2010;12(4):195-8
  8. Waller E.E, Razavi M, Picchi J. Myasthenia Gravis and Hyperthyroidism—A Report of Two Cases Calif Med 1963;99(5): 340–3.
  9. Weetman Ap. Graves’ Dis. N Engl J Med 2000;343: 1236–48.
  10. Knapska-Kucharska M, Oszukowska L, Lewiński A. Analysis of demographic and clinical factors affecting the outcome of radioiodine therapy in patients with hyperthyroidism Arch Med Sci 2010;6(4):611-6. 71
  11. Moura-Neto A, Mosci C, Santos AO, Amorim BJ, de Lima MC, Etchebehere EC, Tambascia MA, Ramos CD, Zantut-Wittmann DE. Predictive factors of failure in a fixed 15 mCi 131I-iodide therapy for Graves’ disease. Clin Nucl Med 2012;37(6):550-4.